



**FOR IMMEDIATE RELEASE**

March 1, 2012

## Methapharm Announces Canadian Distribution of Vancocin<sup>®</sup> (vancomycin hydrochloride, USP)

Merus Labs International Inc. (Merus Labs) announced today that Methapharm Inc. will assume the role of distributor of Vancocin (vancomycin hydrochloride, USP) 125 mg and 250 mg capsules in Canada. Vancocin is indicated for the treatment of enterocolitis caused by *Staphylococcus aureus* (including methicillin-resistant strains) and antibiotic-associated pseudomembranous colitis-caused by *Clostridium difficile*.

### **About Methapharm Inc.**

Methapharm, based in Brantford, Ontario and Coral Springs, Florida is a privately held, full-service specialty pharmaceutical and medical device company offering sales and marketing, regulatory services, market access, and distribution capabilities for product partnership opportunities. Operating in the United States and Canada, we are focused on the commercialization and marketing of specialty pharmaceutical products and medical devices in both countries. We have been inspected by the US FDA and Health Canada. We also hold licenses with respect to prescription pharmaceuticals, medical devices, and other classes of products. Further, we are an ISO 13485:2003 accredited facility.

### **About Merus Labs International Inc.**

Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. The Company utilized its expertise in the North American pharmaceutical markets and its access to capital to acquire and license niche branded products in Canada and the United States. Merus further enhances the sale and distribution of these products by introduction of a focused marketing and promotion plan.

For more information:

Chris Calenti  
General Manager  
Methapharm Inc.  
Tel: (+1) 519-751-3602

[www.methapharm.com](http://www.methapharm.com)